We are live on
!
Find out more
FFM
Fairmount Funds Management Portfolio holdings
AUM
$1.38B
1-Year Est. Return
407.79%
This Fund
S&P 500
This Quarter
Est. Return
+21.35%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$1.23B
AUM Growth
+$348M
(+39%)
Cap. Flow
+$168M
Cap. Flow
% of AUM
13.65%
Top 10 Holdings %
Top 10 Hldgs %
87.85%
Holding
17
New
4
Increased
1
Reduced
3
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ORKA
Oruka Therapeutics
ORKA
|
+$112M |
| 2 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$44.3M |
| 3 |
ZBIO
Zenas BioPharma
ZBIO
|
+$34M |
| 4 |
BCAX
Bicara Therapeutics
BCAX
|
+$32.7M |
| 5 |
Viridian Therapeutics
VRDN
|
+$26.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Protagonist Therapeutics
PTGX
|
+$32.3M |
| 2 |
BCYC
Bicycle Therapeutics
BCYC
|
+$21.8M |
| 3 |
NUVL
Nuvalent
NUVL
|
+$19.7M |
| 4 |
TERN
Terns Pharmaceuticals
TERN
|
+$5.1M |
| 5 |
Dianthus Therapeutics
DNTH
|
+$1.73M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Axsome Therapeutics
AXSM
$12.2B
| $212M | 17.2% |
2,360,077
| – | – |
|
|
NUVL
2
DELISTED
Nuvalent
NUVL
| $173M | 13.99% |
1,687,064
-237,562
| -12% | -$19.7M |
|
3
Apogee Therapeutics
APGE
$10.1B
| $120M | 9.76% |
2,048,647
| – | – |
|
4
Spyre Therapeutics
SYRE
$8.17B
| $118M | 9.58% |
4,018,101
| – | – |
|
5
Enliven Therapeutics
ELVN
$3.63B
| $81.8M | 6.63% |
3,202,798
| – | – |
|
6
Kiniksa Pharmaceuticals
KNSA
$4.7B
| $80.1M | 6.49% |
3,204,841
| – | – |
|
|
ORKA
7
Oruka Therapeutics
ORKA
$5.01B
| $78.7M | 6.38% |
+3,211,922
| New | +$112M |
|
|
8
Viridian Therapeutics
VRDN
$1.99B
| $78.4M | 6.36% |
3,445,813
+1,600,000
| +87% | +$26.2M |
|
|
9
Dianthus Therapeutics
DNTH
$5.21B
| $73.9M | 6% |
2,700,691
-62,146
| -2% | -$1.73M |
|
10
Cogent Biosciences
COGT
$6.48B
| $67.2M | 5.45% |
6,225,641
| – | – |
|
|
DAWN
11
DELISTED
Day One Biopharmaceuticals
DAWN
| $43.2M | 3.51% |
+3,103,448
| New | +$44.3M |
|
|
ATXS
12
DELISTED
Astria Therapeutics
ATXS
| $39.1M | 3.17% |
3,554,129
| – | – |
|
|
BCAX
13
Bicara Therapeutics
BCAX
$1.81B
| $32.7M | 2.65% |
+1,284,169
| New | +$32.7M |
|
|
ZBIO
14
Zenas BioPharma
ZBIO
$1.78B
| $32M | 2.6% |
+1,892,806
| New | +$34M |
|
|
BCYC
15
Bicycle Therapeutics
BCYC
$292M
| $2.8M | 0.23% |
123,538
-945,661
| -88% | -$21.8M |
|
|
16
Protagonist Therapeutics
PTGX
$8.49B
| – | – |
-931,890
| Closed | -$32.3M |
|
|
TERN
17
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-748,996
| Closed | -$5.1M |
|
Similar funds
NIP
OCAM
AU
RIM
VC
AO
1CP
OCM
Fairmount Funds Management's Q3 2024 Portfolio in Review
As of Q3 2024, Fairmount Funds Management held 17 positions worth $1.23B, up 39% from $885M the previous quarter. Its ten largest holdings account for 88% of the portfolio.
Fairmount Funds Management deployed $168M of net new capital in Q3 2024, opening 4 new positions and adding to 1 existing holding. Its largest new stake was Oruka Therapeutics: 3,211,922 shares worth $78.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Bicycle Therapeutics, an estimated $21.8M trimmed.
- Fairmount Funds Management's largest Q3 2024 buy was Oruka Therapeutics: 3,211,922 shares worth $78.7M.
- Fairmount Funds Management added most to Viridian Therapeutics in Q3 2024, an estimated $26.2M increase.
- Fairmount Funds Management's biggest Q3 2024 reduction was Bicycle Therapeutics, cutting an estimated $21.8M.
- Fairmount Funds Management fully exited Protagonist Therapeutics in Q3 2024, selling an estimated $32.3M.
- Fairmount Funds Management's ten largest holdings make up 88% of its $1.23B portfolio in Q3 2024.
- Fairmount Funds Management opened 4 new positions and closed 2 in Q3 2024.
- Fairmount Funds Management's portfolio value rose 39% quarter-over-quarter to $1.23B.
Based on Fairmount Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.